Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Revenue of Liquidia Corporation (LQDA)
Revenue in 2023 (TTM): $17.49 M
According to Liquidia Corporation's latest financial reports the company's current revenue (TTM) is $17.49 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Liquidia Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $17.49 M | $14.6 M | $-70,051,000 | $-78,502,000 | $-78,502,000 |
| 2022 | $15.94 M | $13.08 M | $-34,719,000 | $-41,015,000 | $-38,365,000 |
| 2021 | $12.85 M | $9.83 M | $-27,914,426 | $-34,578,648 | $-29,781,809 |
| 2020 | $739.63 K | $501.92 K | $-55,788,598 | $-59,762,769 | $-57,491,188 |
| 2019 | $8.07 M | $7.26 M | $-43,416,554 | $-47,583,455 | $-46,389,335 |
| 2018 | $2.71 M | $2.59 M | $-32,604,016 | $-53,135,859 | $-53,135,859 |
| 2017 | $7.26 M | $6.94 M | $-15,211,834 | $-29,154,240 | $-29,154,240 |
| 2016 | $13.22 M | $12.3 M | $-15,196,337 | $-15,933,762 | $-15,933,762 |